Target Joint Spontaneous Annualized Bleed Rate Reduction: Results from a Pivotal Trial of Once Weekly BeneFIX (nonacog alfa) in Hemophilia B

Basit Öğe Kaydı
dc.contributor.authorTortella, B.
dc.contributor.authorCarr, M.
dc.contributor.authorRendo, P.
dc.contributor.authorSmith, L.
dc.contributor.authorKavakli, K.
dc.date.accessioned2019-10-27T20:26:07Z
dc.date.available2019-10-27T20:26:07Z
dc.date.issued2015
dc.departmentEge Üniversitesien_US
dc.identifier.endpageE279en_US
dc.identifier.issn1351-8216
dc.identifier.issn1365-2516
dc.identifier.issue3en_US
dc.identifier.startpageE279en_US
dc.identifier.urihttps://hdl.handle.net/11454/42298
dc.identifier.volume21en_US
dc.identifier.wosWOS:000354025900064en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherWiley-Blackwellen_US
dc.relation.ispartofHaemophiliaen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleTarget Joint Spontaneous Annualized Bleed Rate Reduction: Results from a Pivotal Trial of Once Weekly BeneFIX (nonacog alfa) in Hemophilia Ben_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu